secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001193125-25-180771
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data
--------------------------------------------------------------------------------

- Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.
- Cash and cash equivalents $106.1M; raised $69.9M net in June 2025 offering plus $1.7M overallotment.
- Phase 2 celiac disease trial dosing; topline data expected 2026; phase 1b vitiligo data 1H26; alopecia areata initiated with 2026 data.
- Shares outstanding: 12.3M common stock and 5.4M pre-funded warrants as of June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525180771/0001193125-25-180771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525180771/d939022d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-180771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer